|
1
|
Thomas SM and Grandis JR: The current
state of head and neck cancer gene therapy. Hum Gene Ther.
20:1565–1575. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Suh Y, Amelio I, Guerrero Urbano T and
Tavassoli M: Clinical update on cancer: Molecular oncology of head
and neck cancer. Cell Death Dis. 5:e10182014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hashibe M, Brennan P, Benhamou S,
Castellsague X, Chen C, Curado MP, Dal Maso L, Daudt AW, Fabianova
E, Fernandez L, et al: Alcohol drinking in never users of tobacco,
cigarette smoking in never drinkers, and the risk of head and neck
cancer: Pooled analysis in the International Head and Neck Cancer
Epidemiology Consortium. J Natl Cancer Inst. 99:777–789. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Szeszko B, Osowiecka K, Rucińska M,
Wasilewska-Teśluk E, Gliński K and Kepka L: Smoking during
radiotherapy for head and neck cancer and acute mucosal reaction.
Rep Pract Oncol Radiother. 20:299–304. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vojtíšek R, Ferda J and Fínek J:
Effectiveness of PET/CT with (18)F-fluorothymidine in the staging
of patients with squamous cell head and neck carcinomas before
radiotherapy. Rep Pract Oncol Radiother. 20:210–216. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hashibe M, Brennan P, Chuang SC, Boccia S,
Castellsague X, Chen C, Curado MP, Dal Maso L, Daudt AW, Fabianova
E, et al: Interaction between tobacco and alcohol use and the risk
of head and neck cancer: Pooled analysis in the international head
and neck cancer epidemiology consortium. Cancer Epidemiol
Biomarkers Prev. 18:541–550. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen CH and Chen RJ: Prevalence of
telomerase activity in human cancer. J Formos Med Assoc.
110:275–289. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McEachern MJ, Krauskopf A and Blackburn
EH: Telomeres and their control. Annu Rev Genet. 34:331–358. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hug N and Lingner J: Telomere length
homeostasis. Chromosoma. 115:413–425. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bibby MC: An introduction to telomeres and
telomerase. Mol Biotechnol. 24:295–301. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Suchorska WM, Augustyniak E and Łukjanow
M: Genetic stability of pluripotent stem cells during anti-cancer
therapies. Exp Ther Med. 11:695–702. 2016.PubMed/NCBI
|
|
12
|
Chan S and Blackburn EH: Telomeres and
telomerase. Philos Trans R Soc Lond B Biol Sci. 359:109–121. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda
C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL,
Giovanella BC, et al: TERT promoter mutations occur frequently in
gliomas and a subset of tumors derived from cells with low rates of
self-renewal. Proc Natl Acad Sci USA. 110:6021–6026. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jangard M, Zebary A, Ragnarsson-Olding B
and Hansson J: TERT promoter mutations in sinonasal malignant
melanoma: A study of 49 cases. Melanoma Res. 25:185–188. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Khan S, Shukla S, Sinha S and Meeran SM:
Role of adipokines and cytokines in obesity-associated breast
cancer: Therapeutic targets. Cytokine Growth Factor Rev.
24:503–513. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Barczak W, Rozwadowska N, Romaniuk A,
Lipińska N, Lisiak N, Grodecka-Gazdecka S, Książek K and Rubiś B:
Telomere length assessment in leukocytes presents potential
diagnostic value in patients with breast cancer patients. Oncol
Lett. 11:2305–2309. 2016.PubMed/NCBI
|
|
17
|
Cawthon RM: Telomere length measurement by
a novel monochrome multiplex quantitative PCR method. Nucleic Acids
Res. 37:e212009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gruszecka A, Kopczyński P, Cudziło D,
Lipińska N, Romaniuk A, Barczak W, Rozwadowska N, Totoń E and Rubiś
B: Telomere shortening in down syndrome patients-when does it
start? DNA Cell Biol. 34:412–417. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang Y, Sturgis EM, Dahlstrom KR, Wen J,
Liu H, Wei Q, Li G and Liu Z: Telomere length in peripheral blood
lymphocytes contributes to the development of HPV-associated
oropharyngeal carcinoma. Cancer Res. 73:5996–6003. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bau DT, Lippman SM, Xu E, Gong Y, Lee JJ,
Wu X and Gu J: Short telomere lengths in peripheral blood
leukocytes are associated with an increased risk of oral
premalignant lesion and oral squamous cell carcinoma. Cancer.
119:4277–4283. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Z, Ma H, Wei S, Li G, Sturgis EM and
Wei Q: Telomere length and TERT functional polymorphisms are not
associated with risk of squamous cell carcinoma of the head and
neck. Cancer Epidemiol Biomarkers Prev. 20:2642–2645. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Oh BK, Kim H, Park YN, Yoo JE, Choi J, Kim
KS, Lee JJ and Park C: High telomerase activity and long telomeres
in advanced hepatocellular carcinomas with poor prognosis. Lab
Invest. 88:144–152. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vinagre J, Almeida A, Pópulo H, Batista R,
Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, et al:
Frequency of TERT promoter mutations in human cancers. Nat Commun.
4:21852013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vinothkumar V, Arunkumar G, Revathidevi S,
Arun K, Manikandan M, Rao AK, Rajkumar KS, Ajay C, Rajaraman R,
Ramani R, et al: TERT promoter hot spot mutations are frequent in
Indian cervical and oral squamous cell carcinomas. Tumour Biol.
37:7907–7913. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Qu Y, Dang S, Wu K, Shao Y, Yang Q, Ji M,
Shi B and Hou P: TERT promoter mutations predict worse survival in
laryngeal cancer patients. Int J Cancer. 135:1008–1010. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G,
Murugan AK, Guan H, Yu H, Wang Y, et al: TERT promoter mutations
and their association with BRAF V600E mutation and aggressive
clinicopathological characteristics of thyroid cancer. J Clin
Endocrinol Metab. 99:E1130–E1136. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
George JR, Henderson YC, Williams MD,
Roberts DB, Hei H, Lai SY and Clayman GL: Association of TERT
promoter mutation, but not braf mutation, with increased mortality
in PTC. J Clin Endocrinol Metab. 100:E1550–E1159. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu X, Bishop J, Shan Y, Pai S, Liu D,
Murugan AK, Sun H, El-Naggar AK and Xing M: Highly prevalent TERT
promoter mutations in aggressive thyroid cancers. Endocr Relat
Cancer. 20:603–610. 2013. View Article : Google Scholar : PubMed/NCBI
|
